Envveno Medical Corp (NVNO)

$2.77 +0.04 (1.28%)
Market Cap 47.96M
Revenue (ttm) 0.00
Net Income (ttm) -21.82M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 42,447
Avg Vol 91,448
Day's Range N/A - N/A
Shares Out 17.54M
Stochastic %K 91%
Beta 1.04
Analysts Strong Sell
Price Target $16.50

Latest News on NVNO

VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium

Apr 23, 2025, 8:00 AM EDT - 5 days ago

VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium

enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment

Apr 16, 2025, 8:30 AM EDT - 12 days ago

enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment

The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium

Mar 31, 2025, 9:00 AM EDT - 4 weeks ago

The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium

enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25

Feb 28, 2025, 8:00 AM EST - 2 months ago

enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25

enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 19, 2025, 9:00 AM EST - 2 months ago

enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum

Feb 19, 2025, 8:45 AM EST - 2 months ago

One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum

Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting

Feb 7, 2025, 9:00 AM EST - 2 months ago

Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting

enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe

Dec 16, 2024, 8:50 AM EST - 4 months ago

enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe

enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website

Nov 27, 2024, 8:30 AM EST - 5 months ago

enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website

enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium

Nov 20, 2024, 8:30 AM EST - 5 months ago

enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium

enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval

Nov 19, 2024, 8:15 AM EST - 5 months ago

enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval

Hancock Jaffe to Participate in the Duologue Series Virtual Webinar Hosted by Ladenburg Thalmann

Sep 24, 2021, 9:00 AM EDT - 3 years ago

Hancock Jaffe to Participate in the Duologue Series Virtual Webinar Hosted by Ladenburg Thalmann

Hancock Jaffe To Rebrand As enVVeno Medical

Sep 22, 2021, 7:09 AM EDT - 3 years ago

Hancock Jaffe To Rebrand As enVVeno Medical

Hancock Jaffe Announces Corporate Rebranding to Reflect Prioritization of its Development Pipeline on Venous Disease Programs

Sep 21, 2021, 4:00 PM EDT - 3 years ago

Hancock Jaffe Announces Corporate Rebranding to Reflect Prioritization of its Development Pipeline on Venous Disease Programs

Hancock Jaffe to Host Corporate Update Conference Call and Webcast on September 21, 2021

Sep 15, 2021, 8:05 AM EDT - 3 years ago

Hancock Jaffe to Host Corporate Update Conference Call and Webcast on September 21, 2021

Hancock Jaffe Laboratories: Developing Nature-Mimetic Bioprosthetics

Sep 8, 2021, 7:43 PM EDT - 3 years ago

Hancock Jaffe Laboratories: Developing Nature-Mimetic Bioprosthetics

Hancock Jaffe Laboratories Announces $20 Million Registered Direct Offering Priced At-the-Market Under NASDAQ Rules

Sep 7, 2021, 8:05 AM EDT - 3 years ago

Hancock Jaffe Laboratories Announces $20 Million Registered Direct Offering Priced At-the-Market Under NASDAQ Rules

Hancock Jaffe Highlights Two-Year Data For Venous Insufficiency Valve

Aug 19, 2021, 11:49 AM EDT - 4 years ago

Hancock Jaffe Highlights Two-Year Data For Venous Insufficiency Valve

Hancock Jaffe Presents New Positive Two-Year VenoValve Data at the Society for Vascular Surgery Annual Meeting

Aug 19, 2021, 8:00 AM EDT - 4 years ago

Hancock Jaffe Presents New Positive Two-Year VenoValve Data at the Society for Vascular Surgery Annual Meeting

Hancock Jaffe Stock Surges On FDA Breakthrough Designation For Its Venous Insufficiency Device

Aug 3, 2021, 8:58 AM EDT - 4 years ago

Hancock Jaffe Stock Surges On FDA Breakthrough Designation For Its Venous Insufficiency Device

FDA Grants Breakthrough Device Designation Status for Hancock Jaffe's VenoValve

Aug 3, 2021, 8:05 AM EDT - 4 years ago

FDA Grants Breakthrough Device Designation Status for Hancock Jaffe's VenoValve

Hancock Jaffe to Present at the Ladenburg Thalmann 2021 Healthcare Conference

Jul 8, 2021, 9:05 AM EDT - 4 years ago

Hancock Jaffe to Present at the Ladenburg Thalmann 2021 Healthcare Conference

Hancock Jaffe Principal Investigator Dr. Jorge Hernando Ulloa Presents VenoValve One Year First-In-Human Data at Charing Cross International Symposium

Apr 23, 2021, 12:40 PM EDT - 4 years ago

Hancock Jaffe Principal Investigator Dr. Jorge Hernando Ulloa Presents VenoValve One Year First-In-Human Data at Charing Cross International Symposium

First U.S. Patent Issues on Hancock Jaffe VenoValve

Apr 7, 2021, 1:40 PM EDT - 4 years ago

First U.S. Patent Issues on Hancock Jaffe VenoValve

Hancock Jaffe Receives IDE Approval To Begin VenoValve U.S. Pivotal Trial

Apr 5, 2021, 7:30 AM EDT - 4 years ago

Hancock Jaffe Receives IDE Approval To Begin VenoValve U.S. Pivotal Trial

Hancock Jaffe Submits IDE Application to FDA for VenoValve U.S. Pivotal Trial

Mar 8, 2021, 8:30 AM EST - 4 years ago

Hancock Jaffe Submits IDE Application to FDA for VenoValve U.S. Pivotal Trial

Hancock Jaffe Concludes Successful VenoValve Pre-IDE Meeting with FDA

Jan 12, 2021, 8:30 AM EST - 4 years ago

Hancock Jaffe Concludes Successful VenoValve Pre-IDE Meeting with FDA

Hancock Jaffe Announces Executive Promotions

Dec 30, 2020, 4:15 PM EST - 4 years ago

Hancock Jaffe Announces Executive Promotions

Hancock Jaffe Deemed Compliant With All NASDAQ Continued Listing Requirements

Dec 21, 2020, 8:30 AM EST - 4 years ago

Hancock Jaffe Deemed Compliant With All NASDAQ Continued Listing Requirements